TG Therapeutics Shares Rally 8 Sessions on Subcutaneous Briumvi Myasthenia Data
TGTX•TG Therapeutics shares rose for an eighth session, gaining as much as 5% after early data showed subcutaneous Briumvi improved symptoms in 11 myasthenia gravis patients with safety matching the IV formulation. In Q1, Briumvi sales totalled $205 million, and TG Therapeutics raised its 2026 revenue forecast to $925 million.
1. Subcutaneous Briumvi Phase II Trial
TG Therapeutics reported early positive results for a subcutaneous formulation of Briumvi in 11 myasthenia gravis patients, with most subjects experiencing clear symptom improvements after six months and a safety profile comparable to the existing IV treatment.
2. Stock Performance
Shares of TG Therapeutics climbed for eight straight sessions, peaking up 5% intraday on June 17 and closing 2% higher as investor optimism over the new Briumvi data fueled the rally.
3. Financial Update
In the first quarter of 2026, Briumvi generated $205 million in global net sales—$194.8 million in the U.S. and $6.5 million internationally—prompting the company to raise its full-year revenue forecast to $925 million.
